News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amgen (AMGN)'s Third Quarter 2013 Revenues Increased 10 Percent to $4.7 Billion and Adjusted Earnings Per Share (EPS) Increased 16 Percent to $1.94


10/23/2013 6:46:29 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

THOUSAND OAKS, Calif., Oct. 22, 2013 /PRNewswire via COMTEX/ -- Amgen /quotes/zigman/19815/quotes/nls/amgn AMGN -1.02% today announced results for the third quarter of 2013. Key financial results for the quarter include:

-- Total revenues increased 10 percent to $4,748 million, with 11 percent product sales growth driven by strong performance across the portfolio, particularly from Neulasta® (pegfilgrastim), Enbrel® (etanercept), Prolia® (denosumab) and XGEVA® (denosumab). Product sales included a $155 million order for NEUPOGEN® (filgrastim) from the U.S. government.

Help employers find you! Check out all the jobs and post your resume.

Read at Market Watch


comments powered by Disqus
Amgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES